Pipelines in Oncology
To register for these seminars or request a 1:1 meeting with representatives from the presenting company, please visit our events page.
Andree Blaukat, PhD - Senior Vice President and Head of the Translational Innovation Platform Oncology
Stanislaw Mikulski, MD - Senior Medical Director
Lyubomir Vassilev, PhD - Director, Translational & Biomarker Research
Andreas Machl, PhD - Senior Scientist, Translational & Biomarker Research
Bayard Huck, PhD - Program Leader
- A unique PI3K pathway inhibitor simultaneously blocking AKT and p70S6 Kinase
- A potent and selective DNA-PK inhibitor for sensitization to radio- and chemotherapy
Steven H. Stein, MD - Senior Vice President, US Clinical Development & Medical Affairs, Novartis Oncology
Lilli Petruzzelli MD, PhD - Vice President, Oncology Translational Medicine
Barinder Kang, PhD - Director of Clinical Research, Early Development Strategy and Innovation
Amy Williams, PhD - Area Scientific Director – Oncology
Jennifer Adams, RN - Area Scientific Director – Hematology
In addition to the seminar, guests from Novartis will be meeting with investigators at MGH in the morning and DFCI in the afternoon.
Email Andrea Talis (MGH), or Deborah Goff (DFCI) for more details.
Samuel Agresta, MD, MPH & TM/TR - Senior Director and Head of Clinical Development
Dr. Agresta will be meeting with investigators at MGH in the morning and DFCI in the afternoon. If you are interested in a small group or 1:1 meeting with Dr. Agresta, please write to Andrea Talis (MGH), or Deborah Goff (DFCI).
Thomas Zindrick, JD: President and CEO, Genelux Corporation
Aladar A. Szalay, PhD: Founder, Chief Science Advisor, and Former President & CEO, Retired, Genelux Corporation
Tony Yu, PhD: Vice President, Clinical Trials Operations, Genelux Corporation
Professor Yuman Fong, MD: Chief Medical Advisor, Genelux Corporation; Chair, Dept of Surgery, City of Hope, Duarte, CA
Mr John Punty: Chief Financial Officer
Headquartered in San Diego, California, Genelux Corporation is a privately held, clinical stage biopharmaceutical company dedicated to fundamentally changing the way in which cancer is diagnosed and treated. The company has developed a proprietary oncolytic vaccinia virus-based technology platform that can be engineered to insert specific therapeutic genes for delivery and amplification of anti-cancer proteins and RNAs into cancer cells without harming healthy cells. This platform includes a green fluorescent protein (GFP) as a bioluminescent diagnostic. The company is also incorporating advanced diagnostic deep-tissue imaging technologies into its viral platform to enable highly specific visualization of tumors and circulating cancer cells. GL-ONC1, the company’s lead oncology product candidate, is an attenuated vaccinia virus (Lister strain) that is currently under evaluation in multiple human clinical trials in the US and Europe. For more information please visit http://www.genelux.com/